Filing Flows › Akebia Therapeutics (AKBA) › Product revenue, net revenue
Akebia Therapeutics (AKBA) Product revenue, net revenue by quarter
Akebia Therapeutics' Product revenue, net revenue was $34.8M in Q3 2026 (third quarter 2026), -26% from Q2 2026. Over the last 7 quarters it ranged from $34.8M (Q3 2026) to $60.5M (Q2 2025).
| Quarter | Product revenue, net revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $34.8M | -26% | -39% |
| Q2 2026 | $46.8M | -10% | -23% |
| Q1 2026 | $52.0M | -4% | -7% |
| Q4 2025 | $54.3M | -4% | — |
| Q3 2025 | $56.8M | -6% | — |
| Q2 2025 | $60.5M | +8% | — |
| Q1 2025 | $55.8M | — | — |
Q3 2026 at a glance
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Akebia Therapeutics' Product revenue, net revenue?
Akebia Therapeutics' Product revenue, net revenue was $34.8M in Q3 2026 (third quarter 2026), -26% from Q2 2026.
How has Akebia Therapeutics' Product revenue, net revenue changed?
Over the last 7 quarters it ranged from $34.8M (Q3 2026) to $60.5M (Q2 2025).